Lymphoma, Follicular
Showing 26 - 50 of 6,008
Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +6 more
-
Westbury, New YorkClinical Research Alliance Inc
Oct 13, 2023
Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022
Relapsed/Refractory Follicular Lymphoma With EZH2 Trial in Shanghai (Tazemetostat)
Not yet recruiting
- Relapsed/Refractory Follicular Lymphoma With EZH2
-
Shanghai, Shanghai, ChinaShanghai Cancer Center
Jul 20, 2022
People Living With HIV Treated With CD19-directed CAR T Cell
Active, not recruiting
- Leukemia
- +9 more
-
Philadelphia, PennsylvaniaPennsylvania Hospital
Mar 29, 2023
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
Follicular Lymphoma Trial in Miami (Loncastuximab tesirine, Rituximab)
Recruiting
- Follicular Lymphoma
- Loncastuximab tesirine
- Rituximab
-
Miami, FloridaUniversity of Miami
Jul 11, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a Trial in Heidelberg (Standard, Experimental)
Recruiting
- Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
- Standard
- Experimental
-
Heidelberg, GermanyUniversity Hospital Heidelberg
Jul 10, 2022
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma Trial in Cleveland (Med-Jet Injector,
Not yet recruiting
- Mycosis Fungoides of Skin (Diagnosis)
- +5 more
- Med-Jet Injector
- +4 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 17, 2023
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)
Recruiting
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
-
Washington, District of Columbia
- +2 more
Jul 6, 2022
Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Fort Myers, Saint Petersburg, Nashville (Ublituximab, Umbralisib)
Terminated
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
-
Fort Myers, Florida
- +2 more
Jul 20, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Follicular Lymphoma Trial in Duarte, Irvine (procedure, other, biological, drug)
Not yet recruiting
- Follicular Lymphoma
- Biospecimen Collection
- +7 more
-
Duarte, California
- +1 more
Oct 27, 2023
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Active, not recruiting
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Ibrutinib
- +4 more
-
Washington, District of Columbia
- +6 more
Feb 2, 2023
Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)
Withdrawn
- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)
- parsaclisib
- +2 more
- (no location specified)
Jul 14, 2022
Relapsed/Refractory Follicular Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Axicabtagene Ciloleucel
- +8 more
-
Denver, Colorado
- +6 more
Dec 2, 2022
Follicular Lymphoma Trial in Australia (Obinutuzumab 25 MG/1 ML Intravenous Solution, Atezolizumab 1200 MG/40mL Intravenous
Recruiting
- Follicular Lymphoma
- Obinutuzumab 25 MG/1 ML Intravenous Solution
- +2 more
-
Ballarat, Victoria, Australia
- +3 more
Jul 28, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Duarte (Tazemetostat, Ublituximab, Umbralisib)
Not yet recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Tazemetostat
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 31, 2022
Follicular Lymphoma Trial in Boston (Rituximab, Neo Vax, Pembrolizumab)
Recruiting
- Follicular Lymphoma
- Rituximab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 14, 2022